awmsg logo



brimonidine (Mirvaso®)


Reference No. 2168

Publication date:
02/09/2015


Appraisal information

brimonidine (Mirvaso®) 3 mg/g gel


Company: Galderma (UK) Ltd
BNF category: Skin
NMG meeting date: 10/06/2015
AWMSG meeting date: 15/07/2015
   
   
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 2015
Ministerial ratification: 27/08/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Brimonidine (Mirvaso®) is recommended for restricted use within NHS Wales for the symptomatic treatment of facial erythema of rosacea in adult patients. Brimonidine (Mirvaso®) should be restricted for use in patients with moderate to severe persistent facial erythema associated with rosacea. Brimonidine (Mirvaso®) is not recommended for use within NHS Wales outside of this subpopulation.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download